Patterns of use of perioperative angiotensin-converting enzyme inhibitors in coronary artery bypass graft surgery with cardiopulmonary bypass: effects on in-hospital morbidity and mortality
- PMID: 22715473
- DOI: 10.1161/CIRCULATIONAHA.111.059527
Patterns of use of perioperative angiotensin-converting enzyme inhibitors in coronary artery bypass graft surgery with cardiopulmonary bypass: effects on in-hospital morbidity and mortality
Abstract
Background: Despite proven benefit in ambulatory patients with ischemic heart disease, the pattern of use of angiotensin-converting enzyme inhibitors (ACEIs) in coronary artery bypass graft surgery has been erratic and controversial.
Methods and results: This is a prospective observational study of 4224 patients undergoing coronary artery bypass graft surgery. The cohort included 1838 patients receiving ACEI therapy before surgery and 2386 (56.5%) without ACEI exposure. Postoperatively, the pattern of ACEI use yielded 4 groups: continuation, 915 (21.7%); withdrawal, 923 (21.8%); addition, 343 (8.1%); and no ACEI, 2043 (48.4%). Continuous treatment with ACEI versus no ACEI was associated with substantive reductions of risk of nonfatal events (adjusted odds ratio for the composite outcome, 0.69; 95% confidence interval, 0.52-0.91; P=0.009) and a cardiovascular event (odds ratio, 0.64; 95% confidence interval, 0.46-0.88; P=0.006). Addition of ACEI de novo postoperatively compared with no ACEI therapy was also associated with a significant reduction of risk of composite outcome (odds ratio, 0.56; 95% confidence interval, 0.38-0.84; P=0.004) and a cardiovascular event (odds ratio, 0.63; 95% confidence interval, 0.40-0.97; P=0.04). On the other hand, continuous treatment of ACEI versus withdrawal of ACEI was associated with decreased risk of the composite outcome (odds ratio, 0.50; 95% confidence interval, 0.38-0.66; P<0.001), as well as a decrease in cardiac and renal events (P<0.001 and P=0.005, respectively). No differences in in-hospital mortality and cerebral events were noted.
Conclusions: Our study suggests that withdrawal of ACEI treatment after coronary artery bypass graft surgery is associated with nonfatal in-hospital ischemic events. Furthermore, continuation of ACEI or de novo ACEI therapy early after cardiac surgery is associated with improved in-hospital outcomes.
Comment in
-
About fACE: perioperative use of angiotensin-converting enzyme inhibitors.Circulation. 2012 Jul 17;126(3):249-51. doi: 10.1161/CIRCULATIONAHA.112.117671. Epub 2012 Jun 19. Circulation. 2012. PMID: 22715474 Free PMC article. No abstract available.
Similar articles
-
Preoperative statin therapy is associated with reduced cardiac mortality after coronary artery bypass graft surgery.J Thorac Cardiovasc Surg. 2006 Aug;132(2):392-400. doi: 10.1016/j.jtcvs.2006.04.009. J Thorac Cardiovasc Surg. 2006. PMID: 16872968
-
Which patients should be on renin-angiotensin system blockers after coronary surgery?Interact Cardiovasc Thorac Surg. 2014 Oct;19(4):667-72. doi: 10.1093/icvts/ivu211. Epub 2014 Jul 4. Interact Cardiovasc Thorac Surg. 2014. PMID: 24997188 Review.
-
Effects of angiotensin-converting enzyme inhibitor therapy on clinical outcome in patients undergoing coronary artery bypass grafting.J Am Coll Cardiol. 2009 Nov 3;54(19):1778-84. doi: 10.1016/j.jacc.2009.07.008. Epub 2009 Aug 13. J Am Coll Cardiol. 2009. PMID: 19682819
-
Comparison of coronary bypass surgery with and without cardiopulmonary bypass in patients with multivessel disease.J Thorac Cardiovasc Surg. 2004 Jan;127(1):167-73. doi: 10.1016/j.jtcvs.2003.08.032. J Thorac Cardiovasc Surg. 2004. PMID: 14752427
-
Effect of preoperative angiotensin-converting enzyme inhibitor on the outcome of coronary artery bypass graft surgery.Eur J Cardiothorac Surg. 2015 May;47(5):788-95. doi: 10.1093/ejcts/ezu298. Epub 2014 Jul 30. Eur J Cardiothorac Surg. 2015. PMID: 25079771 Review.
Cited by
-
Pre-operative maintenance of angiotensin-converting enzyme inhibitors is not associated with acute kidney injury in cardiac surgery patients with cardio-pulmonary bypass: a propensity-matched multicentric analysis.Front Pharmacol. 2024 May 1;15:1343647. doi: 10.3389/fphar.2024.1343647. eCollection 2024. Front Pharmacol. 2024. PMID: 38783960 Free PMC article.
-
Hemodynamic effects of withholding vs. continuing angiotensin II receptor blockers on the day of prone positioning spinal surgery in elderly patients.Front Med (Lausanne). 2024 May 3;11:1352918. doi: 10.3389/fmed.2024.1352918. eCollection 2024. Front Med (Lausanne). 2024. PMID: 38765256 Free PMC article.
-
Continuing versus withholding angiotensin receptor blocker (ARB)/calcium channel blocker (CCB) combination tablets during perioperative periods in patients undergoing minor surgery: a single-blinded randomized controlled trial.J Anesth. 2022 Jun;36(3):374-382. doi: 10.1007/s00540-022-03053-8. Epub 2022 Mar 5. J Anesth. 2022. PMID: 35247102 Free PMC article. Clinical Trial.
-
Impact of Renin-Angiotensin System Blockers on Mortality in Veterans Undergoing Cardiac Surgery.J Am Heart Assoc. 2021 May 18;10(10):e019731. doi: 10.1161/JAHA.120.019731. Epub 2021 May 8. J Am Heart Assoc. 2021. PMID: 33969701 Free PMC article.
-
Neuroprotection against stroke and encephalopathy after cardiac surgery.Interv Med Appl Sci. 2019 Mar;11(1):27-37. doi: 10.1556/1646.11.2019.01. Interv Med Appl Sci. 2019. PMID: 32148901 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical

